TME Pharma N.V. (ALTME) - Cash Flow Conversion Efficiency

Latest as of June 2025: 5.018x

Based on the latest financial reports, TME Pharma N.V. (ALTME) has a cash flow conversion efficiency ratio of 5.018x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.86 Million ≈ $-3.34 Million USD) by net assets (€-570.00K ≈ $-666.39K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

TME Pharma N.V. - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how TME Pharma N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALTME total debt and obligations for a breakdown of total debt and financial obligations.

TME Pharma N.V. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TME Pharma N.V. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
BPH Energy Ltd AU:BPH	-0.008x
Next Technology Holding Inc NASDAQ:NXTT	0.006x
Premier Products Public Company Limited BK:PPP	0.045x
Red Sky Energy Ltd AU:ROG	0.032x
Allergy Therapeutics LSE:AGY	0.748x
Iron Road Ltd AU:IRD	-0.021x
NFI Octava SA WAR:08N	-0.022x
Kiora Pharmaceuticals Inc NASDAQ:KPRX	-0.057x

Annual Cash Flow Conversion Efficiency for TME Pharma N.V. (2014–2024)

The table below shows the annual cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of TME Pharma N.V..

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€1.61 Million ≈ $1.89 Million	€-4.63 Million ≈ $-5.42 Million	-2.871x	-114.98%
2023-12-31	€-294.00K ≈ $-343.72K	€-5.63 Million ≈ $-6.59 Million	19.167x	+100.77%
2022-12-31	€-1.27 Million ≈ $-1.49 Million	€-12.14 Million ≈ $-14.20 Million	9.546x	+447.13%
2021-12-31	€4.50 Million ≈ $5.26 Million	€-12.38 Million ≈ $-14.47 Million	-2.750x	-305.25%
2020-12-31	€7.70 Million ≈ $9.00 Million	€-5.22 Million ≈ $-6.11 Million	-0.679x	-129.36%
2019-12-31	€-1.85 Million ≈ $-2.17 Million	€-4.29 Million ≈ $-5.01 Million	2.312x	+50.67%
2018-12-31	€-2.61 Million ≈ $-3.05 Million	€-4.00 Million ≈ $-4.68 Million	1.534x	+41.92%
2017-12-31	€-3.92 Million ≈ $-4.58 Million	€-4.24 Million ≈ $-4.95 Million	1.081x	-70.15%
2016-12-31	€-2.48 Million ≈ $-2.90 Million	€-8.99 Million ≈ $-10.51 Million	3.622x	+88.94%
2015-12-31	€-7.03 Million ≈ $-8.22 Million	€-13.48 Million ≈ $-15.76 Million	1.917x	-3.93%
2014-12-31	€-6.24 Million ≈ $-7.30 Million	€-12.46 Million ≈ $-14.57 Million	1.996x	--

About TME Pharma N.V.

PA:ALTME France Biotechnology

Market Cap

$8.56 Million

€7.32 Million EUR

Market Cap Rank

#27472 Global

#488 in France

Share Price

€0.08

Change (1 day)

+1.04%

52-Week Range

€0.05 - €0.12

All Time High

€1994.22